Transoral robotic surgery for oropharyngeal carcinoma: Surgical margins and oncologic outcomes

Head & Neck ◽  
2018 ◽  
Vol 40 (4) ◽  
pp. 747-755 ◽  
Author(s):  
Eric J. Moore ◽  
Kathryn M. Van Abel ◽  
Daniel L. Price ◽  
Christine M. Lohse ◽  
Kerry D. Olsen ◽  
...  
Keyword(s):  
Robotic Surgery ◽  
Transoral Robotic Surgery ◽  
Surgical Margins ◽  
Oncologic Outcomes ◽  
Oropharyngeal Carcinoma

scholarly journals Oncologic Outcomes Following Transoral Robotic Surgery for Human Papillomavirus–Associated Oropharyngeal Carcinoma in Older Patients

2020 ◽  
Vol 146 (12) ◽  
pp. 1167
Author(s):  
Harman S. Parhar ◽  
David Shimunov ◽  
Jason G. Newman ◽  
Steven B. Cannady ◽  
Karthik Rajasekaran ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Robotic Surgery ◽  
Older Patients ◽  
Transoral Robotic Surgery ◽  
Oncologic Outcomes ◽  
Oropharyngeal Carcinoma

Muscle invasion in oropharyngeal carcinoma undergoing transoral robotic surgery

Head & Neck ◽  
2020 ◽  
Author(s):  
Robert M. McKenzie ◽  
Harman S. Parhar ◽  
Tony L. Ng ◽  
Eitan Prisman
Keyword(s):  
Robotic Surgery ◽  
Transoral Robotic Surgery ◽  
Oropharyngeal Carcinoma ◽  
Muscle Invasion

scholarly journals Development of an online, patient-centred decision aid for patients with oropharyngeal cancer in the transoral robotic surgery era

2017 ◽  
Vol 24 (5) ◽  
pp. 318 ◽  
Author(s):  
J.S. Lam ◽  
G.M. Scott ◽  
D.A. Palma ◽  
K. Fung ◽  
A.V. Louie
Keyword(s):  
Robotic Surgery ◽  
Oropharyngeal Cancer ◽  
Decision Aid ◽  
Transoral Robotic Surgery ◽  
Oncologic Outcomes ◽  
Patient Treatment ◽  
Promising Alternative ◽  
Trade Off ◽  
Cure Rates ◽  
Adult Volunteers

Background  Radiotherapy (rt) has been the standard treatment for early oropharyngeal cancer, achieving excellent outcomes, but with significant toxicities. Transoral robotic surgery (tors) has emerged as a promising alternative. A decision aid (da) can help to establish patient treatment preferences.Methods A da was developed and piloted in 40 healthy adult volunteers. Assuming equal oncologic outcomes of the treatments, participants indicated their preference. The treatment trade-off point was then established, and participant perceptions were elicited.Results More than 80% of participants initially selected tors for treatment, regardless of facilitator background. For all participants, the treatment trade-off point changed after an average 15% cure benefit. Treatment toxicities, duration, novelty, and perceptions all influenced treatment selection. All subjects valued the da.Conclusions A da developed for early oropharyngeal cancer treatment holds promise in the era of shared decision making. Assuming equal cure rates, tors was preferred over rt by healthy volunteers.

scholarly journals Oncologic Outcomes After Transoral Robotic Surgery

2015 ◽  
Vol 141 (12) ◽  
pp. 1043 ◽  
Author(s):  
John R. de Almeida ◽  
Ryan Li ◽  
J. Scott Magnuson ◽  
Richard V. Smith ◽  
Eric Moore ◽  
...  
Keyword(s):  
Robotic Surgery ◽  
Transoral Robotic Surgery ◽  
Oncologic Outcomes

Transoral robotic surgery: A multicenter study to assess feasibility, safety, and surgical margins

2012 ◽  
Vol 122 (8) ◽  
pp. 1701-1707 ◽  
Author(s):  
Gregory S. Weinstein ◽  
Bert W. O'Malley ◽  
J. Scott Magnuson ◽  
William R. Carroll ◽  
Kerry D. Olsen ◽  
...  
Keyword(s):  
Robotic Surgery ◽  
Multicenter Study ◽  
Transoral Robotic Surgery ◽  
Surgical Margins

scholarly journals Transoral Robotic Surgery (TORS) for the Head and Neck: Current and Future Indications

2010 ◽  
Vol 1 (3) ◽  
pp. 133-140 ◽  
Author(s):  
Harry Quon ◽  
Bert W O'Malley ◽  
Gregory S Weinstein
Keyword(s):  
Robotic Surgery ◽  
Head And Neck ◽  
Malignant Tumors ◽  
Infratemporal Fossa ◽  
Transoral Robotic Surgery ◽  
Oncologic Outcomes ◽  
Surgical Approaches ◽  
Malignant Diseases ◽  
Treatment Team ◽  
Federal Drug Administration

Abstract Transoral robotic surgery (TORS) offers many technical advancements to existing endoscopic and transoral surgical approaches. This has faciliated a safer, less morbid and potentially more effective application of surgery to the management of both benign and malignant diseases in the head and neck. As this surgical approach gains widespread acceptance, it is important for all members of the treatment team to understand the strengths and current limitations especially when TORS is applied for malignant diseases. As of December 2009, Federal Drug Administration (FDA) has approved the use of the da Vinci® surgical system and TORS for selected malignancies of the oral cavity, pharynx and larynx and all benign disease. Of these sites, the greatest experience and longest duration of follow-up has been in the use of TORS for the management of oropharyngeal carcinomas where at least comparable oncologic outcomes and reduced long-term feeding tube dependency rates have been reported. Other anatomic sites where TORS has shown benefit based on preclinical studies and early human experiences include the larynx, hypopharynx, parapharyngeal space and infratemporal fossa for both benign and selected malignant tumors. Experience to date has demonstrated that the improved visualization with the robotic system offers the potential for improved oncologic resection with reduced morbidity. Based on present studies and outcomes data in conjunction with ongoing investigations, it is anticipated that TORS will make a major impact in the way we manage benign and malignant tumors within the head and neck and skull base.

Sign in / Sign up

Export Citation Format

Share Document